Terms: = Leukemia AND FUS, P35637, 2521, ENSG00000089280, TLS/CHOP, FUS-CHOP, CHOP, FUS1, TLS AND Treatment
474 results:
1. A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia.
Manda S; Anz BM; Benton C; Broun ER; Yimer HA; Renshaw JS; Geils G; Berdeja J; Cruz J; Melear JM; Fanning S; Fletcher L; Li Y; Duan Y; Werner ME; Potluri J; Pai MV; Donnellan WB
Hematol Oncol; 2024 May; 42(3):e3274. PubMed ID: 38711253
[TBL] [Abstract] [Full Text] [Related]
2. treatment patterns, clinical outcomes and gene mutation characteristics of hepatitis B virus-associated mantle cell lymphoma.
Feng J; Fei Y; Gao M; Meng X; Zeng D; Zou D; Ye H; Liang Y; Sun X; Liang R; Zhou H; Wang X; Zhang H
Hematol Oncol; 2024 May; 42(3):e3268. PubMed ID: 38676394
[TBL] [Abstract] [Full Text] [Related]
3. A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia.
Hampel PJ; Swaminathan M; Rogers KA; Parry EM; Burger JA; Davids MS; Ding W; Ferrajoli A; Hyak JM; Jain N; Kenderian SS; Wang Y; Wierda WG; Woyach JA; Parikh SA; Thompson PA
Blood Adv; 2024 May; 8(10):2342-2350. PubMed ID: 38537065
[TBL] [Abstract] [Full Text] [Related]
4. Low incidence of tumor lysis syndrome in elderly patients with chronic lymphocytic leukemia treated with venetoclax under real-world conditions: results from the prospective observational VeRVe study.
Schwaner I; Kuhn T; Losem C; Wolff T; Otremba B; Zaiss M; Hülsenbeck J; Famulla K; Nösslinger T; Rossi D
Ann Hematol; 2024 Jun; 103(6):2013-2020. PubMed ID: 38421404
[TBL] [Abstract] [Full Text] [Related]
5. Venetoclax combined with decitabine induced tumor lysis syndrome in a young patient with acute myeloid leukemia: a case report and literature review.
Zhang H; Liu J; Wu Q; Xia L
Anticancer Drugs; 2024 Jun; 35(5):440-444. PubMed ID: 38386312
[TBL] [Abstract] [Full Text] [Related]
6. Management and use of healthcare resources in patients with chronic lymphocytic leukemia initiating venetoclax in routine clinical practice.
Banerji V; Aw A; Laferriere N; Abdel-Samad N; Peters A; Johnson NA; Bernard MP; Gopalakrishnan S; Bull SJ; Fournier PA; Klil-Drori AJ; Hay AE; Robinson S; Owen C
Leuk Lymphoma; 2024 May; 65(5):609-617. PubMed ID: 38235709
[TBL] [Abstract] [Full Text] [Related]
7. Genetic and transcriptomic analyses of diffuse large B-cell lymphoma patients with poor outcomes within two years of diagnosis.
Ren W; Wan H; Own SA; Berglund M; Wang X; Yang M; Li X; Liu D; Ye X; Sonnevi K; Enblad G; Amini RM; Sander B; Wu K; Zhang H; Wahlin BE; Smedby KE; Pan-Hammarström Q
Leukemia; 2024 Mar; 38(3):610-620. PubMed ID: 38158444
[TBL] [Abstract] [Full Text] [Related]
8. Synergistic lethality in chronic myeloid leukemia - targeting oxidative phosphorylation and unfolded protein response effectively complements tyrosine kinase inhibitor treatment.
Häselbarth L; Gamali S; Saul D; Krumbholz M; Böttcher-Loschinski R; Böttcher M; Zou D; Metzler M; Karow A; Mougiakakos D
BMC Cancer; 2023 Nov; 23(1):1153. PubMed ID: 38012567
[TBL] [Abstract] [Full Text] [Related]
9. SOHO State-of-the-Art Updates and Next Questions: treatment for Newly Diagnosed Peripheral T-Cell Lymphomas.
Burton JS; Foley NC; Mehta-Shah N
Clin Lymphoma Myeloma Leuk; 2024 Feb; 24(2):65-76. PubMed ID: 37973458
[TBL] [Abstract] [Full Text] [Related]
10. Tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax and hypomethylating agents with or without dose ramp-up.
Khouderchah CJ; Benitez LL; Marini BL; Fraga M; Pettit K; Burke PW; Bixby DL; Perissinotti AJ
Leuk Lymphoma; 2024 Feb; 65(2):228-234. PubMed ID: 37933203
[TBL] [Abstract] [Full Text] [Related]
11. [Adult T-cell leukemia/lymphoma].
Yoshimitsu M
Rinsho Ketsueki; 2023; 64(9):1032-1040. PubMed ID: 37899180
[TBL] [Abstract] [Full Text] [Related]
12. Divergent CD4
Khelfa M; Leclerc M; Kerbrat S; Boudjemai YNS; Benchouaia M; Neyrinck-Leglantier D; Cagnet L; Berradhia L; Tamagne M; Croisille L; Pirenne F; Maury S; Vingert B
Front Immunol; 2023; 14():1165973. PubMed ID: 37701444
[TBL] [Abstract] [Full Text] [Related]
13. Real-world time to discontinuation of first-line venetoclax + obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma.
Lu X; Emond B; Qureshi ZP; Wu LH; Forbes SP; Hilts A; Liu S; Lafeuille MH; Lefebvre P; Huang Q; Rogers KA
Curr Med Res Opin; 2023 Sep; 39(9):1227-1235. PubMed ID: 37530387
[TBL] [Abstract] [Full Text] [Related]
14. Metformin sensitizes AML cells to venetoclax through endoplasmic reticulum stress-chop pathway.
Hua L; Yang N; Li Y; Huang K; Jiang X; Liu F; Yu Z; Chen J; Lai J; Du J; Zeng H
Br J Haematol; 2023 Sep; 202(5):971-984. PubMed ID: 37409755
[TBL] [Abstract] [Full Text] [Related]
15. The comprehensive expression of BCL2 family genes determines the prognosis of diffuse large B-cell lymphoma.
Roh J; Pak HK; Jeong S; Hwang S; Kim DE; Choi HS; Kim SJ; Kim H; Cho H; Park JS; Jeong SH; Choi YS; Han JH; Yoon DH; Park CS
Biochem Biophys Res Commun; 2023 Sep; 673():36-43. PubMed ID: 37356143
[TBL] [Abstract] [Full Text] [Related]
16. Adverse Event Profile of Azacitidine: Analysis by Route of Administration Using Japanese Pharmacovigilance Database.
Yamaoka K; Fujiwara M; Uchida M; Uesawa Y; Muroi N; Shimizu T
Oncology; 2023; 101(10):664-674. PubMed ID: 37279701
[TBL] [Abstract] [Full Text] [Related]
17. An update on the efficacy of Venetoclax for chronic lymphocytic leukemia.
Lovell AR; Sawyers J; Bose P
Expert Opin Pharmacother; 2023; 24(11):1307-1316. PubMed ID: 37226798
[TBL] [Abstract] [Full Text] [Related]
18. Melatonin Can Enhance the Effect of Drugs Used in the treatment of leukemia.
Lomovsky AI; Baburina YL; Fadeev RS; Lomovskaya YV; Kobyakova MI; Krestinin RR; Sotnikova LD; Krestinina OV
Biochemistry (Mosc); 2023 Jan; 88(1):73-85. PubMed ID: 37068876
[TBL] [Abstract] [Full Text] [Related]
19. Characterization of a multidisciplinary team's role in hospital discharge for patients receiving hypomethylating agents with venetoclax as induction therapy for acute myeloid leukemia.
Pervitsky V; Guglielmo J; Moskoff B; Kneen R; Leija C; Sawicky D; Krackeler ML; Jonas BA; Beechinor R
Support Care Cancer; 2023 Mar; 31(4):224. PubMed ID: 36941508
[TBL] [Abstract] [Full Text] [Related]
20. Immune priming with avelumab and rituximab prior to R-chop in diffuse large B-cell lymphoma: the phase II AvR-chop study.
Manos K; Chong G; Keane C; Lee ST; Smith C; Churilov L; McKendrick J; Renwick W; Blombery P; Burgess M; Nelson NE; Fancourt T; Hawking J; Lin W; Scott AM; Barraclough A; Wight J; Grigg A; Fong CY; Hawkes EA
Leukemia; 2023 May; 37(5):1092-1102. PubMed ID: 36906715
[TBL] [Abstract] [Full Text] [Related]
[Next]
